Spyglass Capital Management LLC Acquires 64,610 Shares of Medpace Holdings, Inc. $MEDP

Spyglass Capital Management LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 115.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 120,365 shares of the company’s stock after acquiring an additional 64,610 shares during the period. Medpace comprises about 3.5% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Spyglass Capital Management LLC owned about 0.43% of Medpace worth $63,744,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of MEDP. Two Sigma Securities LLC raised its position in shares of Medpace by 158.9% during the second quarter. Two Sigma Securities LLC now owns 1,877 shares of the company’s stock worth $994,000 after purchasing an additional 1,152 shares during the period. GTS Securities LLC acquired a new position in shares of Medpace in the 2nd quarter valued at approximately $201,000. Cookson Peirce & Co. Inc. grew its position in shares of Medpace by 5.9% in the 2nd quarter. Cookson Peirce & Co. Inc. now owns 965 shares of the company’s stock valued at $511,000 after purchasing an additional 54 shares during the period. Van ECK Associates Corp increased its stake in Medpace by 0.3% during the 2nd quarter. Van ECK Associates Corp now owns 24,835 shares of the company’s stock worth $13,152,000 after purchasing an additional 76 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. increased its stake in Medpace by 4.5% during the 2nd quarter. Campbell Newman Asset Management Inc. now owns 9,604 shares of the company’s stock worth $5,086,000 after purchasing an additional 416 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Down 1.1%

Shares of MEDP opened at $593.99 on Tuesday. The company’s fifty day simple moving average is $568.10 and its 200 day simple moving average is $495.34. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a market cap of $16.58 billion, a price-to-earnings ratio of 34.82, a PEG ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 earnings per share. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on MEDP shares. Robert W. Baird lifted their price target on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Royal Bank Of Canada boosted their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Medpace has an average rating of “Hold” and a consensus price target of $584.18.

Insider Activity

In related news, CEO August J. Troendle sold 650 shares of Medpace stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the transaction, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the transaction, the director directly owned 27,825 shares in the company, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 134,471 shares of company stock valued at $82,151,311. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.